Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | BRD4 | O60885 | 3/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | PARP1 | P09874 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30516131 | 1.00 | CYP2C9 (1.00) | CYP2C9MEN1KMT2ACYP3A4TDP1 | |
| SCHEMBL30625698 | 0.91 | KDM4E (0.83) | CYP2C9MEN1KMT2ACYP3A4TDP1 | |
| SCHEMBL17273902 | 0.84 | KMT2A (0.70) | CYP2C9MEN1KMT2ACYP3A4TDP1 | |
| SCHEMBL20211622 | 0.74 | MEN1 (0.58) | CYP2C9MEN1KMT2ACYP3A4TDP1 | |
| SCHEMBL15537236 | 0.74 | MEN1 (0.58) | CYP2C9MEN1KMT2ACYP3A4TDP1 | |
| SCHEMBL30516134 | 0.74 | MEN1 (0.58) | CYP2C9MEN1KMT2ACYP3A4TDP1 | |
| SCHEMBL4969510 | 0.70 | PARP1 (1.00) | CYP2C9MEN1KMT2ACYP3A4TDP1 | |
| SCHEMBL18132580 | 0.70 | MAPT (0.73) | CYP2C9MEN1KMT2ACYP3A4TDP1 | |
| SCHEMBL22173221 | 0.70 | MAPT (0.68) | CYP2C9MEN1KMT2ACYP3A4TDP1 | |
| SCHEMBL25149031 | 0.70 | LMNA (1.00) | CYP2C9MEN1KMT2ACYP3A4ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4302833-A2 | COMPOSITIONS FOR MODULATING PD-1 SIGNAL TRANSDUCTION | Augusta University Research Institute, Inc. (US) | 2024-01-10 | — | — | EP | claimed |
| EP-3548022-B1 | COMPOSITIONS FOR MODULATING PD-1 SIGNAL TRANSDUCTION | UNIV RES INST INC AUGUSTA (US) | 2023-11-22 | — | — | EP | claimed |
| CN-116585315-A | Compositions for modulating PD-1 signaling | 奥古斯塔大学研究所公司 | 2023-08-15 | — | — | CN | claimed |
| US-20200147091-A1 | COMPOSITIONS FOR MODULATING PD-1 SIGNAL TRANSDUCTION | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. | 2020-05-14 | — | — | US | claimed |
| EP-3548022-A1 | COMPOSITIONS FOR MODULATING PD-1 SIGNAL TRANSDUCTION | Augusta University Research Institute, Inc. (US) | 2019-10-09 | — | — | EP | claimed |
| US-20180153898-A1 | COMPOSITIONS FOR MODULATING PD-1 SIGNAL TRANSDUCTION | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. | 2018-06-07 | — | — | US | claimed |
| WO-2018100556-A1 | COMPOSITIONS FOR MODULATING PD-1 SIGNAL TRANSDUCTION | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (US) | 2018-06-07 | — | — | WO | claimed |
| US-20150337018-A1 | USE OF COMPOUNDS THAT SELECTIVELY MODULATE ASTROCYTIC RELEASE OF SUBSTANCES THROUGH HEMICHANNELS OF CONNEXINS AND PANNEXINS, WITHOUT INFLUENCING GAP JUNCTIONS, FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | UNIVERSIDAD ANDRES BELLO (CL) | 2015-11-26 | — | — | US | claimed |
| EP-2897632-A2 | COMPOUNDS MODULATING ASTROCYTIC RELEASE OF SUBSTANCES THROUGH CONNEXINS AND PANNEXINS AND TREATMENT OF PSYCHIATRIC DISORDERS | Universidad Andres Bello (CL) | 2015-07-29 | — | — | EP | claimed |
| WO-2013179264-A2 | USE OF COMPOUNDS THAT SELECTIVELY MODULATE ASTROCYTIC RELEASE OF SUBSTANCES THROUGH HEMICHANNELS OF CONNEXINS AND PANNEXINS, WITHOUT INFLUENCING GAP JUNCTIONS, FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | UNIVERSIDAD ANDRES BELLO (CL) | 2013-12-05 | — | — | WO | claimed |
| EP-4302833-A2 | COMPOSITIONS FOR MODULATING PD-1 SIGNAL TRANSDUCTION | Augusta University Research Institute, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| EP-3548022-B1 | COMPOSITIONS FOR MODULATING PD-1 SIGNAL TRANSDUCTION | UNIV RES INST INC AUGUSTA (US) | 2023-11-22 | — | — | EP | disclosed |
| CN-116585315-A | Compositions for modulating PD-1 signaling | 奥古斯塔大学研究所公司 | 2023-08-15 | — | — | CN | disclosed |
| US-20200147091-A1 | COMPOSITIONS FOR MODULATING PD-1 SIGNAL TRANSDUCTION | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. | 2020-05-14 | — | — | US | disclosed |
| EP-3548022-A1 | COMPOSITIONS FOR MODULATING PD-1 SIGNAL TRANSDUCTION | Augusta University Research Institute, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| EP-2897632-A2 | COMPOUNDS MODULATING ASTROCYTIC RELEASE OF SUBSTANCES THROUGH CONNEXINS AND PANNEXINS AND TREATMENT OF PSYCHIATRIC DISORDERS | Universidad Andres Bello (CL) | 2015-07-29 | — | — | EP | disclosed |
| WO-2013179264-A2 | USE OF COMPOUNDS THAT SELECTIVELY MODULATE ASTROCYTIC RELEASE OF SUBSTANCES THROUGH HEMICHANNELS OF CONNEXINS AND PANNEXINS, WITHOUT INFLUENCING GAP JUNCTIONS, FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | UNIVERSIDAD ANDRES BELLO (CL) | 2013-12-05 | — | — | WO | disclosed |
| US-20110275558-A1 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275558-A1 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275558-A1 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275558-A1 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | LANCL2, ACSL1, LANCL1 | CYP2C9 4737/4885MEN1 4389/4885KMT2A 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.